{"id":"b9479a085d86","type":"article","url":"https://hartvaat.nl/2026/12/01/obesitas-en-diabetes-stijgen-maar-ckd-prevalentie-blijft-stabiel-20-jaar-nhanes-/","title":"Obesitas en diabetes stijgen, maar CKD-prevalentie blijft stabiel — 20-jaar NHANES-analyse","title_en":"Comprehensive trends in Chronic Kidney Disease prevalence and comorbidities across eGFR and albuminuria categories: a 20-year analysis of NHANES data.","category":"chronische nierziekte","category_label":"Nierziekte","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Renal failure","doi":"10.1080/0886022X.2025.2536192","source_url":"https://doi.org/10.1080/0886022X.2025.2536192","authors":["Youssef Mk Farag","Zihe Zheng","Aqsa H Dar","Anam Tariq"],"significance":5,"published":"2026-09-22","source_date":"2026-12-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/nierziekte-en-cardiovasculair-risico/","https://hartvaat.nl/kennis/cardiometabool/diabetes-en-cardiovasculair-risico/"],"congress":"","summary_en":"A 20-year analysis of NHANES data (1999–2018) reveals a stable CKD prevalence of 20% among US adults, despite the adoption of the race-neutral CKD-EPI 2021 equation. While obesity and diabetes rates rose significantly, hypertension, anemia, hyperkalemia, and cardiovascular disease remained stable over the period. Patients in the KDIGO G3bA2 and G4A1 categories carry the highest comorbidity burden. These trends highlight the need for risk-stratified, individualized management strategies that address the specific metabolic and cardiovascular profiles of CKD patients.","created":"2026-09-16T00:47:55Z","updated":"2026-09-16T00:47:55Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een analyse van 20 jaar NHANES-gegevens (1999-2018) toont een stabiele prevalentie van chronische nierziekte (CKD) van 20% bij volwassenen in de VS, ondanks de invoering van de racevrije CKD-EPI 2021-formule. De prevalentie van obesitas en diabetes nam significant toe, terwijl hypertensie, anemie, hyperkalemie en cardiovasculaire ziekte stabiel bleven. Patiënten in de KDIGO-categorieën G3bA2 en G4A1 lopen het grootste risico op comorbiditeiten. Deze bevindingen onderstrepen de noodzaak van een geïndividualiseerde zorgstrategie die rekening houdt met de specifieke nierfunctie en het comorbiditeitsprofiel.","abstract_original":"Chronic kidney disease (CKD) represents a major public health challenge, contributing to over 1.2 million global deaths annually and ranking as the 12th leading cause of mortality. This study provides a 20-year trend analysis (1999-2018) of CKD prevalence and its associated comorbidities among adults in the United States using the NHANES dataset. Employing the CKD-EPI 2021 equation without the race component, the study revealed a stable CKD prevalence of 20% in adults aged ≥20 years, alongside trends in nine comorbidities. Obesity and diabetes showed significant increases, while hypertension, anemia, hyperkalemia, and cardiovascular disease remained stable. Hypertriglyceridemia and hypercholesterolemia exhibited an initial rise followed by a plateau. The analysis highlights the uneven distribution of CKD comorbidities across KDIGO-defined eGFR and albuminuria subcategories, with G3bA2 and G4A1 patients at heightened risk. These findings underscore the importance of targeted interventions through an individualized care strategy that considers CKD risk category and the comorbidities profiles. Additionally, it offers pivotal epidemiological insights to inform clinical research, policymaking, and precision medicine in nephrology."}